Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, United States16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Recruiting | Phase 3 | 2026-10-08 | NCT07623200 | |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-05 | NCT06982521 | |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | Extensive Stage-small Cell Lung Cancer | Recruiting | Phase 1 / Phase 2 | 2026-10-01 | NCT06362252 | |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-09-30 | NCT07015242 | |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | Adnexal Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, endometrium neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinoma, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-24 | NCT04590326 | |
| Luspatercept + Darbepoetin in MDS | Hemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia | Recruiting | Phase 2 | 2026-09-14 | NCT07096297 | |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, acute leukemia, acute myeloid leukemia, acute myeloid leukemia with mutated NPM1, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-08-20 | NCT06001788 | |
| Busulfan Sample Collection Study | Subjects Treated With Busulfan | Recruiting | Not stated | 2026-07-30 | NCT05711732 | |
| International Registry for Men With Advanced Prostate Cancer (IRONMAN) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Not stated | 2026-05-22 | NCT03151629 | |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute biphenotypic leukemia, acute leukemia of ambiguous lineage, acute myeloid leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, mixed phenotype acute leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-13 | NCT04067336 | |
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-04-06 | NCT05382299 | |
| 9-ING-41 in Patients With Advanced Cancers | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Leukemia-Lymphoma, Adult T-Cell, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, T-cell leukemia, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bone cancer, bone disorder, bone neoplasm, breast disorder, breast neoplasm, cancer, central nervous system malformation, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, glioma, hematologic disorder, hereditary disease, hereditary sensory and autonomic neuropathy, immune system disorder, immunoproliferative disorder, inherited neurodegenerative disorder, intestinal disorder, kidney cancer, kidney disorder, leukemia, lung disorder, lung neoplasm, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant endocrine neoplasm, malignant glioma, malignant pancreatic neoplasm, musculoskeletal system disorder, neoplasm, nervous system disorder, neurodegenerative disease, neuroepithelial neoplasm, neuromuscular disease, pancreas disorder, pancreatic adenocarcinoma, pancreatic neoplasm, peripheral nervous system disorder, polyneuropathy, primitive neuroectodermal tumor, rectal disorder, refractory malignant neoplasm, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, urinary system disorder | Active, not recruiting | Phase 2 | 2026-04-03 | NCT03678883 | |
| The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 1 / Phase 2 | 2026-03-27 | NCT05756322 | |
| Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, carcinoma, cervix disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, head and neck squamous cell carcinoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, squamous cell carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-20 | NCT02503423 | |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, acute myeloid leukemia, acute myeloid leukemia with mutated NPM1, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myeloid leukemia, myeloid sarcoma, neoplasm, sarcoma | Recruiting | Phase 1 | 2026-03-13 | NCT05735184 | |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2025-09-18 | NCT05382286 |